Amryt Pharma Share Discussion Threads

[greendragon777] 11/10/2017 11:02

Haha....shame on you Paps for even thinking it was me! 😁 I'm more committed than ever and I'm stocking up on the popcorn for the ride up in 2018....wouldn't miss it for the world!

Whoever sold it is gonna be absolutely kicking themselves this time next year!

[papillon] 11/10/2017 10:40

Yes I noticed that 611,000 trade/sell @ 20p yesterday, ccr1958. It wasn't made after hours; it was just reported (at 6.23pm) after the market closed. It was possibly a worked trade that was completed yesterday and the reporting was delayed because of it's size.

So come on; which shareholder who posts on this bb sold 611,000 shares? LOL.

Somebody was desperate to sell their shares. Was it you greendragon? LOL.

[ccr1958] 11/10/2017 07:58

Yes pale, got to spend their dough somewhere ;), no that is obviously positive !!

[paleje] 11/10/2017 07:42

Fair bit of director buying announced this morning though.

[ccr1958] 11/10/2017 07:36

Big sell 611k shares after hours last night @20p..

[papillon] 10/10/2017 11:48

Nice 125k buy @ full asking price of 21.50p this morning.

[papillon] 09/10/2017 19:29

Well at least almost all of the BoD have put their hands in their pockets and taken part in the placing:

Harry Stratford has bought 150,000 (£30k)
Joe Willey has bought 221,592 (£44.3k). He now holds 20,994,487 shares
Rory Nealon has also bought 221,592 (£44.3k) He now holds 9,664,623 shares
James Culverwell has also bought 221,592 (£44.3k)
Markus Ziener has bought 132,955 (£26.5k). He now holds 232,955 shares

Ray Stafford didn't take part, but he already holds 2,296,369 shares

So all the BoD are now shareholders and now circa 12% of the shares in issue. That's positive.

Software AG Stiftung holds 22.3% of the AMYT shares in issue following the placing.

[papillon] 09/10/2017 12:06

"I thought it would be in the teens by now." It would be, Jackson, if it hadn't been for the 2 pieces of good news released in the past year: namely the 20m Euro loan and the Lojuxta deal with Novelion. Without those 2 deals I think it likely the AMYT share price would have even dropped below the circa 14p low achieved just before those 2 deals were announced. Without those 2 deals they would have had to raise far more money than they have raised in this latest placing. Without those 2 deals I suspect the AMYT share price could have been back in single figures by now!

However AMYT did announce those 2 deals and I can't see the share price dropping below 20p. If one was an optimist one could hope for another licensing deal aka Lojuxta before the first AP101 trial results are issued.

PS. Ignoring the presentations, which have no impact on the sp, there have been 3 significant RNS's issued in the past 12 months. 2 have contained good news; the EIB loan and the Lojuxta deal. Both were good for the share price There has ONLY been ONE placing in the past 12 months and that has been bad for the sp!

[jacksonpollack] 09/10/2017 09:32

I've got to say I'm surprised the share price has held up so well over the past year given that not much news apart from below share price placings has been forthcoming. I thought it would be in the teens by now. Papillon keep up the good work. It does sound over the past few weeks that your patience is being tested here, but I think it will be worth the wait. Agree with others here that nothing is going to happen till at least Q2 next year so I'm still out till at least Q1 2018.

[waterloo01] 09/10/2017 06:54

Thanks Timbo

[timbo003] 09/10/2017 00:54

Amryt presentation at Proactiveinvestor (Oct 5th 2017)

Rory Nealon (CFO) gave the presentation, the slide set used was a cut down version of the Sept 2017 corporate presentation on the Amryt web site:


The missing slides were 9, 13, 18, 20, 22, 23, 32, 33, 34, 35 and 36.

At Proactive, the presenters only get 20 minutes to run through their presentations and 5 - 10 minutes for questions, so there was little time to dwell on any particular aspect, but there were a couple of parts of RN’s narrative which caught my attention:

Slide 4: Amryt have a very experienced management team and contains three former Aegerion senior staff/directors, these three have extremely extensive knowledge of Lojuxta and Lojuxta’s clinical development history (also see notes from the Shard Capital meeting below)

Slide 8: The deal Amryt struck with Aegerion (now merged QTL and renamed Novelion) was exceptional by industry standards, as it was negotiated in record time, there were no upfront payments and the Royalties/sales milestone payments are not onerous.

Slide 12: the photo on the LHS is a receptacle containing fat (as an emulsion) extracted from the blood of one HoFH patient by Apheresis, patients may have to undergo this procedure every 2 weeks.

Slide 37: Note the position of interim analysis star (April/May?) and topline data star (Sept/Oct?) on the Gant chart for AP101. RN didn’t mention dates, just H1 for interim analysis and H2 for topline data, but he did say numbers of patients may be adjusted at the interim analysis stage to ensure 80% power for the completed study.


There was only time for a couple of Q&As, see summary below which is in note form and should not be considered a verbatim account:

Q: Would you expect Lojuxta to have any effect on non-HoFH patients, i.e. the millions of people who have moderately high levels of cholesterol and hence an increased risk of Cardiovascular problems? If so, could Lojuxta ever be prescribed for this large patient group?

A: Lojuxta should be effective in lowering cholesterol in some non-HoFH patients, however, there would be a real risk of liver damage (fatty liver, possibly leading to cirrhosis). Furthermore, it would be necessary to maintain patients on a very low fat diet or risks of hepatic problems would be exacerbated, furthermore patients would require frequent liver function tests. Therefore it is probable that Lojuxsta will never be used for these patients, even after the patents expire and cheaper generics become available,(see Lojuxta SPC for side effects and contra indications):


Q: Did the competitor to AP101 for EB (Zorblisa) have any reasonably decent phase II data and should the recent failure of Zorblisa in a Phase III study give us any cause for concerns regarding the ongoing AP101 Phase III study?

A: We always thought the Zorblisa phase II data was a bit suspect, but there was a reluctance to express that opinion whilst their phase III study was ongoing. The failure of the Zorblisa trial does not change our outlook for the ongoing AP101 study, our phase II data looked more robust and furthermore we already have the product approved (but not launched) for another indication (partial thickness wounds).



Meeting with Shard Capital and Amryt management (June 14th 2017)


Lojuxta:

The deal struck with Aegerion concerning Lojuxta (lomitapide) for the treatment of HoFH was exceptional. It was fortuitous for Amryt that Aegerion were under intense pressure to do a deal by November 30th 2016, as that was a condition for the imminent merger between Aegerion and QLT to proceed.

The merger was completed on November 29th and the Amryt deal on Lojuxta was announced soon thereafter



Aegerion had been forced into this corporate action as a result of improper promotion of Juxtapid (lomitapide) the US version of Lojuxta. This has since lead to US litigation and a substantial fine for Aegerion (Novelion)


One highly significant factor in Amryt’s favour when negotiating with Aegerion was that Amryt’s Chief Medical officer (Mark Sumeray) had left Aegerion to join Amryt. MS had extensive knowledge of Lojuxta ,which helped speed the Due Diligence process and gave comfort to Aegerion that Lojuxta would be properly nurtured under Aegerion’s stewardship. The deal was negotiated in record time (3 months vs industry average of 18 months).


Familial hypercholesterolaemia (FH) is caused by a defective LDL receptor gene which is responsible for generating the enzyme which removes LDL cholesterol from the systemic circulation, fortunately these defects are relatively rare:

* 1 in 1,000,000 are homozygotes (HoFH)
* 1 in 250 (approx.) are heterozygotes (HeFH)

Lojuxta is not indicated for heterozygotes and it is only indicated for around 50% of homozygotes (i.e. those 50% who do not respond to PSK9 inhibitors such as evolocumab and alirocumab)

There is some overlap between homozygotes and heterozygotes for severity on some of the symptoms and for a definitive diagnosis genotyping would be required, However healthcare payers and arbitrators such as Nice have not insisted on genotyping, even though the cost of treatment with Lojuxta is around 260K Euros/year/patient.


Standard of Care (SOC) for HOF patients (before Lojuxta and PCSK9 inhibitors came along) included Apheresis every 2 weeks (similar to kidney dialysis but worse) to extract LDL cholesterol from blood.

Patients taking Lojuxta need to go on a low fat diet (<20% of calories derived from fat).

HoFH patients who stop taking Lojuxta may do so because they cannot stick to the low fat diet (they experience diarrhoea if they take in too much fat) or they show substantially elevated liver enzymes, or because they die from their condition.

One further clinical trial is planned under a paediatric investigation plan (PIP) which will give extended protection for Lojuxta beyond patent expiry in Europe. This will involve conducting clinical studies in paediatric patients at an estimated cost of $9m (funded by Amryt). The starting dose will be 2mg (starting dose in adults is 5mg), sourcing the clinical materials will be relatively easy as Lojuxta is formulated as a capsule, rather than a tablet.

AP101

Patent protection extends through to 2030, it is a method of use patent for Birch bark extract/Betuline and any related compounds for the treatment EB.

There is some IP around the competitor product Zorblisa (allantoin) which involves stabilisation of the formula.

Amicus acquired Zorblisa (Scioderm) for $840m in August 2015


Compare and contrast this figure with the market cap of Amryt at around £45m (which corresponds to a share price of around 22p)


AP102

The analysts currently assign a zero value to AP102, this should change as preparations are made for a phase I clinical which is due to commence beginning of Q1 2018.

[papillon] 07/10/2017 11:13

Yes, it is funny, waterloo.

[waterloo01] 06/10/2017 16:28

Pap this one is for you. I dare you not to laugh. Have a good weekend.

[greendragon777] 06/10/2017 16:27

20 bagger....we love those apples Paps. That said I'll settle for a 10 bagger too! Haha

[papillon] 06/10/2017 16:07

The company is doing all these presentations to put it on investors radar; to get it known. However that doesn't mean anyone is going to buy the shares based on a presentation. Getting the company noticed could, however, help the share price when the next good (hopefully!) news is released. AIM shares move upwards on good news, or the expectation of good news.

As small PI's we have 3 options: sell, add, or hold. I'm going to hold and if I have any spare cash, add a few more, but 20k of shares is my limit. I don't want to gamble more than I can afford to lose. Not that I think I will lose too much, but if AP101 doesn't cut the mustard then my dreams of a 10, or even 20, bagger from the current share price will prove to be just so much wishful thinking on my part!

[greendragon777] 06/10/2017 15:11

That's not good enough Timboo....can the missus and MiL not wait, we need an update here! Haha

Miniscule volumes today but maybe investors are out enjoying the last of the good weather....plenty of time to pour their millions into AMYT over the winter! 😁

[timbo003] 06/10/2017 11:59

Rory gave the presentation last night, the slide set should be available later, I'm out with the Missus and the MiL today, so will do a few notes when i get back

[papillon] 06/10/2017 11:48

The market has been open for 3 hours 35 minutes and the number of AMYT shares traded so far is a BIG FAT ZERO! LOL.

Presentations are not going to push up the AMYT share price Only a GOOD NEWS RNS, which will attract all the rampers and pumpers and dumpers on the message boards, will do that! Nothing new about a company is ever released at a presentation; it's only laying out what we already know; what's already in the public domain.

We'll just have to be patient and wait for that good news RNS. We could have to be patient and wait until the AP101 news next year. We could be lucky and get news of another Lojuxta type deal in the meantime, or someone like Amicus buying shares in the market, but don't bank on it!

[greendragon777] 06/10/2017 10:34

Haha....maybe it's the calm before the storm and the investors are dumping all their other holdings so they can barrel into AMYT! :-)

[waterloo01] 06/10/2017 10:28

Indeed I'm impressed, not often you get zero volume.

[bazworth] 06/10/2017 10:27

waterloo01 - can't you sense that it was an outrageous success by the massive volume traded so far today!!

[waterloo01] 06/10/2017 10:10

Timbo, how was the event?

[papillon] 05/10/2017 12:02

AMYT personnel wont be able to give answers to an individual tonight that contain potentially price sensitive information.

[greendragon777] 05/10/2017 10:48

Great Timboo thanks for the heads up. It would be great if you could ask him about the Amicus deal and if he thinks a similar one could be put in place for similar numbers for AP101 immediately after the interim results in H1 next year. ie- £250m down and milestone payments up to £800m on approval etc.

Thanks a mil and good luck tonight. Look forward to hearing how it went.